As the novel coronavirus disease 2019 (COVID-19) pandemic began in December 2019, children were reported to be at lower risk of developing severe symptoms or critical illness compared with adults with a large study from China demonstrating critical illness in \<1% of children.[@bib1] ^,^ [@bib2] Preliminary studies from Europe and the US have provided early data on critically ill children.[@bib3], [@bib4], [@bib5], [@bib6], [@bib7]

The clinical manifestations, including pulmonary findings, and outcomes of critically ill children with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been described only in a small number of cases, and the factors associated with development of progressive critical illness and mortality are unclear. The objectives of this study are to describe the clinical manifestations of critically ill children with COVID-19 admitted to pediatric intensive care units (PICUs) across New York City during the first wave of the US pandemic and to identify factors associated with PICU and hospital length of stay (LOS).

Methods {#sec1}
=======

The Albert Einstein College of Medicine institutional review board reviewed and approved this multicenter retrospective observational study. The institutional review boards at each individual center approved this study, as applicable. Only deidentified data were transmitted and analyzed. Informed consent was waived.

We identified critically ill pediatric patients 1 month to 21 years of age with confirmed SARS-CoV-2 infection from March 14 to May 2, 2020 (7 weeks) admitted to 9 New York City teaching hospitals (Children\'s Hospital at Montefiore, New York-Presbyterian Morgan Stanley Children\'s Hospital of New York, Kravis Children\'s Hospital at Mount Sinai, State University of New York Downstate Medical Center, Jacobi Medical Center, Kings County Medical Center, Lincoln Medical and Mental Health Center, The Brooklyn Hospital Center, and Richmond University Medical Center) located in 4 of 5 boroughs of New York City with a total catchment area encompassing all 5 boroughs ([Figure 1](#figE1){ref-type="fig"}; available at [www.jpeds.com](http://www.jpeds.com){#intref0010}). These 9 of 25 PICUs (approximately 46% of the PICU beds) in New York City were included as collaborators were able to obtain institutional review board approval in time for enrollment.

A COVID-19 case was defined as due to SARS-CoV-2 infection by a positive real-time reverse transcription polymerase chain reaction test of a specimen using nasopharyngeal swab, using one of several different testing platforms due to institutional preference, as well as limited testing kits in the early phase of the pandemic (Abbott Laboratories, Abbot Park, Illinois; Bioreference Laboratories, Elmwood, New Jersey; Cepheid Xpert Xpress, Sunnyvale, California; Hologic Panther Fusion, San Diego, California; LabCorp, Raritan, New Jersey; Luminex Aries; Northwell Health Laboratories, Lake Success, New York; New York City Department of Health and Mental Hygiene Public Health Laboratory; Roche diagnostics, Basel, Switzerland). Patients with the more recently recognized entity of multisystem inflammatory syndrome in children (MIS-C) were not represented in this study because the description was defined, and cases began to occur after the study time period.

Data from each institution\'s electronic medical record were obtained through a research form in Research Electronic Data Capture software (REDCap, Vanderbilt University, Nashville, Tennessee). Demographic and clinical data and laboratory and radiologic results were obtained. All tests and treatments were performed at the discretion of the treating physicians.

A total of 31 of the 70 patients described in this study were included in other published reports, including 3 patients who met criteria the Centers for Disease Control use definition for MIS-C.[@bib5] ^,^ [@bib6] ^,^ [@bib8], [@bib9], [@bib10]

Definitions {#sec1.1}
-----------

Acute respiratory distress syndrome (ARDS) was defined using Pediatric Acute Respiratory Distress criteria[@bib11]: oxygenation index (OI) 4-8 or oxygen saturation index (OSI) 5-7.5 as mild-severity ARDS, OI 8-16 or OSI 7.5-12.3 as moderate-severity ARDS, and OI \>16 or OSI \>12.5 as severe ARDS. Management of ARDS was at the discretion of the treating physician and generally was based on Pediatric Acute Respiratory Distress recommendations of low tidal volume and limiting plateau pressure to ≤30 cm of water.[@bib11] ^,^ [@bib12] Acute kidney injury (AKI) was defined using the Kidney Disease: Improving Global Outcomes classification based upon a change in serum creatinine level and creatinine clearance.[@bib13] Sepsis, severe sepsis, and septic shock were defined using the Pediatric Surviving Sepsis Guidelines.[@bib14] Virus-associated sepsis was defined as the presence of ≥2 systemic inflammatory syndrome criteria; severe sepsis as sepsis with organ dysfunction or tissue hypoperfusion; and septic shock as severe sepsis with volume-refractory hypotension.[@bib14] Obesity was considered a comorbidity and was defined as body mass index (BMI) \>30 kg/m^2^. Asthma was considered a respiratory comorbidity. Severity of illness was described using Pediatric Index of Mortality-2 (PIM-2) scores, and standardized mortality ratio was calculated as standardized mortality ratio = observed mortality of our cohort/expected mortality using PIM-2 score.[@bib15]

Outcomes {#sec1.2}
--------

Outcomes reported included need for invasive mechanical ventilation, PICU LOS, hospital LOS, and mortality within the first 14 days and 28 days of PICU admission.

Statistical Analyses {#sec1.3}
--------------------

Demographic and clinical characteristics were summarized as frequencies and percentages for categorical variables, as medians and IQRs for continuous variables, and compared between patients with and without ARDS by using χ^2^ test or Fisher exact test, and Wilcoxon rank-sum test for categorical and continuous variables, respectively. Patients were followed up at 14 days and 28 days from PICU admission, and Kaplan--Meier curves of PICU and hospital LOS were compared in patients with and without ARDS using log-rank tests. Cox proportional hazards regression was employed to investigate the association of presence of ARDS with PICU and hospital discharges, adjusting for need for mechanical ventilation during PICU stay and platelet count measured on admission day 1 in multivariable analyses. *P* \< .05 was considered statistically significant. Data were analyzed by using SAS software (version 9.4; SAS Institute Inc, Cary, North Carolina).

Results {#sec2}
=======

Seventy children with COVID-19 were hospitalized in the PICUs of the 9 participating hospitals in New York City from March 14 to May 2, 2020. Thirty-three (47%) patients were from the borough of the Bronx and 16 (22.8%) from the borough of Brooklyn ([Figure 1](#figE1){ref-type="fig"}).

Of the 70 patients, 21 (30%) had a diagnosis of ARDS within the first 14 days of hospitalization. Demographics and baseline characteristics of the whole cohort as well as for those with and without ARDS are shown in [Table I](#tbl1){ref-type="table"} . Forty-three (61.4%) patients were male; 27 (38.6%) were Hispanic, and 23 (32.9%) were black. Median age was 15 years (IQR 9, 19); median weight was 56.6 kg (IQR 27.7, 96.1) and BMI was 22.7 kg/m^2^ (IQR 19.1, 32.7). Fifty-two patients (74.3%) had at least 1 comorbidity. Severity of illness on admission was not significantly different between the ARDS and non-ARDS groups, as reflected by PIM-2 scores on PICU admission with overall risk of mortality of 0.8% (IQR 0.2%, 1.4%).Table IDemographics and baseline characteristics of critically ill pediatric patients with COVID-19CharacteristicsTotal (n = 70)No ARDS (n = 49)ARDS (n = 21)*P* value[∗](#tbl1fnlowast){ref-type="table-fn"}Age, y, median (IQR)15.0 (9.0, 19.0)15.0 (11.0, 18.0)14.0 (9.0, 19.0).7237Sex Female, n (%)27 (38.6)19 (38.8)8 (38.1).9573 Male, n (%)43 (61.4)30 (61.2)13 (61.9)Race Black, n (%)23 (32.9)19 (38.8)4 (19.0).1699 White, n (%)7 (10.0)6 (12.2)1 (4.8) Latino, n (%)27 (38.6)15 (30.6)12 (57.1) Other, n (%)13 (18.6)9 (18.4)4 (19.0)Weight, kg, median (IQR)56.6 (27.7, 96.1)63.4 (27.7, 96.1)45.2 (28.0, 83.8).8526BMI, kg/m^2^, median (IQR) \[n = 66\]22.7 (19.1, 32.7)23.5 (19.2, 32.7)21.4 (19.1, 30.6).9561PIM-2 score: % risk of mortality, median (IQR) \[n = 69\]0.8 (0.2, 1.4)0.8 (0.2, 1.8)0.8 (0.4, 1.3).6417Comorbidities Obesity (BMI\>30), n (%) \[n = 66\]20 (30.3)13 (28.9)7 (33.3).7144 BMI \>35, n (%) \[n = 66\]14 (21.2)9 (20.0)5 (23.8).7534 BMI \>40, n (%) \[n = 66\]12 (18.2)8 (17.8)4 (19.0)1.0000 BMI \>50, n (%) \[n = 66\]4 (6.1)2 (4.4)2 (9.5).5865 Respiratory, n (%)17 (24.3)10 (20.4)7 (33.3).2478 Heart disease, n (%)4 (5.7)3 (6.1)1 (4.8)1.0000 Hematologic/malignancy/immunosuppression, n (%)12 (17.1)8 (16.3)4 (19.0).7432 Diabetes/prediabetes, n (%)9 (12.9)7 (14.3)2 (9.5).7140 Neurologic, n (%)10 (14.3)5 (10.2)5 (23.8).1536 2 or more comorbidities, n (%)18 (25.7)12 (24.5)6 (28.6).7203 3 or more comorbidities, n (%)2 (2.9)0 (0.0)2 (9.5).0870Presenting symptoms/history Cough, n (%)50 (71.4)34 (69.4)16 (76.2).5637 Fever, n (%)51 (72.9)34 (69.4)17 (81.0).3187 Shortness of breath, n (%)45 (64.3)26 (53.1)19 (90.5).0028 Headache, n (%)15 (21.4)9 (18.4)6 (28.6).3564 Rhinorrhea, n (%)9 (12.9)4 (8.2)5 (23.8).1155 Nausea/vomiting, n (%)24 (34.3)20 (40.8)4 (19.0).0787 Diarrhea, n (%)18 (25.7)12 (24.5)6 (28.6).7203 Myalgias, n (%)13 (18.6)10 (20.4)3 (14.3).7410 Known sick contacts, n (%) \[n = 11 missing\]30 (50.8)19 (47.5)11 (57.9).4555 Travel history in past month, n (%)2 (2.9)1 (2.0)1 (4.8).5130 Duration of symptoms before admission, d, median (IQR) \[n = 1 missing\]5.0 (2.0, 7.0)4.0 (2.0, 8.5)5.0 (3.0, 7.0).7626Vital signs on admission Temp, °C, median (IQR)37.5 (36.9, 38.3)37.4 (36.9, 38.3)37.5 (37.0, 37.9).7923 Heart Rate, bpm, median (IQR)107.0 (99.0, 129.0)107.0 (101.0, 131.0)107.0 (99.0, 123.0).6628 SBP, mm Hg, median (IQR)114.0 (101.0, 126.0)116.0 (102.0, 126.0)105.0 (95.0, 124.0).1421 DBP, mm Hg, median (IQR)68.5 (58.0, 77.0)69.0 (58.0, 79.0)68.0 (58.0, 72.0).6909 RR, bpm, median (IQR)26.0 (22.0, 38.0)25.0 (22.0, 36.0)32.0 (26.0, 42.0).0724 SpO~2~ percentage, median (IQR)98.0 (96.0, 99.0)98.0 (96.0, 99.0)97.0 (94.0, 99.0).2375Admission diagnosis Respiratory failure, n (%)47 (67.1)26 (53.1)21 (100.0).0090 Shock, n (%)5 (7.1)5 (10.2)0 (0.0) Sepsis, n (%)5 (7.1)5 (10.2)0 (0.0) DKA, n (%)7 (10.0)7 (14.3)0 (0.0) Seizures/neuro, n (%)5 (7.1)5 (10.2)0 (0.0) Other, n (%)1 (1.4)1 (2.0)0 (0.0)[^2][^3]

Fever (72.9%) and cough (71.4%) were the most common presenting symptoms. Ninety percent of patients who developed ARDS came to medical attention with dyspnea, compared with 53.1% who did not develop ARDS (*P* = .003). Median duration of symptoms before hospitalization was 5 days (IQR 2.0, 7.0), and a known sick contact was reported in 50.8% of patients.

[Table II](#tbl2){ref-type="table"} summarizes the laboratory and radiographic testing results. The median total white blood cell count for the entire cohort of patients was 8.8 (IQR 6.3, 13.0) k/μL; median absolute lymphocyte count was 1.1 (IQR 0.6,2.0) k/μL. Patients with ARDS had significantly lower platelet counts compared with those without ARDS (169 \[IQR 110, 242\] k/μL vs 216 \[IQR 159, 309\] k/μL, *P* = .04). Serum levels of C-reactive protein, procalcitonin, lactate, pro-B type natriuretic peptide, and interleukin-6 were elevated among patients with ARDS, but levels were statistically significantly different than patients without ARDS only for interleukin-6 (78.7 \[IQR 34, 201.5\] vs 16.4 \[IQR 12.1, 66\] pg/mL, *P* = .03). Eight patients had positive blood cultures; 3 patients had positive respiratory tract cultures, and 5 patients had positive urine cultures; concomitant respiratory infections were reported in 3 patients (4.3%) with rhinovirus in 2 and *Bordetella pertussis* in 1.Table IIResults of laboratory imaging studies on admission to PICUVariablesTotal (n = 70)No ARDS (n = 49)ARDS (n = 21)*P* value[∗](#tbl2fnlowast){ref-type="table-fn"}WBC, k/μL, median (IQR) \[n = 69\]8.8 (6.3, 13.0)8.8 (6.3, 11.7)8.9 (6.0, 14.3).9105Absolute lymphocyte count, cells/μL, median (IQR) \[n = 69\]1117.4 (610.9, 1998.4)1001.6 (604.5, 2258.7)1177.0 (766.3, 1914.9).3936Hemoglobin, g/dL, median (IQR) \[n = 69\]12.2 (10.8, 14.6)12.9 (11.1, 14.7)11.9 (9.6, 13.2).1815Platelets, k/μL, median (IQR) \[n = 69\]198.0 (147.0, 264.0)216.0 (159.0, 309.0)169.0 (110.0, 242.0).0430AST, U/L, median (IQR) \[n = 60\]36.0 (28.0, 60.0)33.0 (27.0, 57.0)40.0 (32.0, 61.0).3691ALT, U/L, median (IQR) \[n = 60\]26.0 (14.5, 49.5)30.0 (15.0, 56.0)20.0 (12.0, 45.0).1870Total bilirubin, mg/dL, median (IQR) \[n = 60\]0.4 (0.2, 0.9)0.4 (0.2, 1.0)0.3 (0.1, 0.9).1987BUN, mg/dL, median (IQR)11.0 (8.0, 14.0)10.0 (8.0, 13.0)11.0 (7.0, 15.0).6528Creatinine, mg/dL, median (IQR)0.7 (0.5, 0.9)0.7 (0.5, 0.9)0.6 (0.4, 0.9).7728C-reactive protein, mg/dL, median (IQR) \[n = 48\]6.8 (2.6, 14.9)6.0 (2.5, 26.0)8.1 (3.5, 11.8).8716Procalcitonin, ng/mL, median (IQR) \[n = 34\]0.2 (0.1, 0.9)0.2 (0.1, 0.6)0.4 (0.2, 1.1).1778Pro-BNP, pg/mL, median (IQR) \[n = 14\]940.0 (92.0, 4289.0)440.8 (60.0, 4289.0)1734.0 (1112.0, 15 000.0).1195Troponin, ng/mL, median (IQR) \[n = 32\]0.0 (0.0, 0.0)0.0 (0.0, 0.0)0.0 (0.0, 0.1).6109CPK, U/L, median (IQR) \[n = 25\]120.0 (74.0, 302.0)128.5 (74.0, 316.0)99.0 (60.0, 302.0)1.0000Lactate, mmol/L, median (IQR) \[n = 43\]1.5 (1.2, 2.5)1.6 (1.2, 2.6)1.5 (1.3, 2.3).5972D-dimer, μg/mL FEU, median (IQR) \[n = 35\]2.3 (0.8, 161.0)3.1 (0.8, 161.0)2.0 (0.7, 20.0).8663LDH, U/L, median (IQR) \[n = 39\]370.0 (289.0, 524.0)318.0 (276.0, 461.0)421.0 (344.0, 569.0).0413IL-6, pg/mL, median (IQR) (n = 23)42 (13.7, 112)16.4 (12.1, 66)78.7 (34, 201.5).0316+Blood culture, n (%)8 (11.8)4 (8.5)4 (19.0).2403+Respiratory culture, n (%)3 (5.2)0 (0.0)3 (14.3).0431+Urine culture, n (%)5 (8.2)1 (2.5)4 (19.0).0437Chest radiograph Clear, n (%)12 (17.1)12 (24.5)0 (0.0).0133 B/L infiltrates, n (%)35 (50.0)20 (40.8)15 (71.4).0189 Pleural effusions, n (%)4 (5.7)1 (2.0)3 (14.3).0776 Pneumothorax, n (%)1 (1.4)0 (0.0)1 (4.8).3000 Other, n (%)16 (22.9)10 (20.4)6 (28.6).5383 LV dysfunction by echocardiogram, n (%)6 (40.0)3 (33.3)3 (50.0).6224 LV EF percentage, median (IQR) \[n = 3\]44.1 (25.0, 48.7)48.7 (48.7, 48.7)34.6 (25.0, 44.1).5403 RV dysfunction by echocardiogram, n (%) \[n = 3\]3 (20.0)2 (22.2)1 (16.7)1.0000[^4][^5]

On chest radiography, 71% of patients with ARDS had bilateral infiltrates compared with 41% of those without ARDS (*P* = .02). Fifteen patients had documented formal echocardiograms performed, of who 6 had left ventricular dysfunction, and 3 had right ventricular dysfunction.

Medical Therapy and Outcomes {#sec2.1}
----------------------------

As presented in [Table III](#tbl3){ref-type="table"} , 57 patients met criteria for sepsis, of whom 12 patients met criteria for severe sepsis. Ten of these 12 patients meeting severe sepsis criteria also had ARDS compared with 2 in the non-ARDS group (*P* \< .0001). Fourteen patients (20%) required vasopressor support: 11 in the ARDS group vs 3 in the non-ARDS group (*P* \< .0001), with norepinephrine being the most frequently used vasopressor medication. Nine patients (12.9%) had AKI, and 1 patient required renal-replacement therapy.Table IIITherapies and clinical outcomesCharacteristicsTotal (n = 70)No ARDS (n = 49)ARDS (n = 21)*P* value[∗](#tbl3fnlowast){ref-type="table-fn"}Medical therapy Hydroxychloroquine, n (%)27 (38.6)14 (28.6)13 (61.9).0087 Azithromycin, n (%)23 (32.9)16 (32.7)7 (33.3).9557 Remdesivir, n (%)13 (18.6)6 (12.2)7 (33.3).0494 Corticosteroid, n (%)23 (32.9)13 (26.5)10 (47.6).0852 IL-6 inhibitor, n (%)3 (4.3)3 (6.1)0 (0.0).5488 IL-1 inhibitor, n (%)1 (1.4)1 (2.0)0 (0.0)1.0000 Antibiotics \<48 h, n (%)20 (28.6)17 (34.7)3 (14.3).0833 Antibiotics \>48 h, n (%)28 (40.0)13 (26.5)15 (71.4).0004Vasopressor use Any inotrope use, n (%)14 (20.0)3 (6.1)11 (52.4)\<.0001 Epinephrine, n (%)3 (4.3)1 (2.0)2 (9.5).2123 Norepinephrine, n (%)8 (11.4)2 (4.1)6 (28.6).0074 Dopamine, n (%)5 (7.1)1 (2.0)4 (19.0).0259 Dobutamine, n (%)1 (1.4)1 (2.0)0 (0.0)1.0000 Milrinone, n (%)3 (4.3)2 (4.1)1 (4.8)1.0000Respiratory support NC oxygen, n (%)30 (42.9)18 (36.7)12 (57.1).1138 Duration of NC oxygen, h, median (IQR)27.5 (9.0, 36.0)28.0 (10.0, 48.0)15.5 (6.5, 25.5).3125 HFNC oxygen, n (%)21 (30.0)14 (28.6)7 (33.3).6903 Duration of HFNC oxygen, h, median (IQR)96.0 (59.0, 108.0)96.0 (87.0, 108.0)8.0 (8.0, 8.0).1349 Non-IMV, CPAP, or BiPAP, n (%)14 (20.0)4 (8.2)10 (47.6).0004 Total duration of non-IMV/CPAP/BiPAP, h, median (IQR)79.5 (41.5, 121.5)156.0 (156.0, 156.0)72.0 (11.0, 87.0).3711 IMV, n (%)20 (28.6)2 (4.1)18 (85.7)\<.0001 Extubated, n (%)9 (45.0)1 (50.0)8 (44.4)1.0000 Duration of IMV, h, median (IQR) \[among 9 extubated patients\]163.0 (79.0, 308.7)79.0 (79.0, 79.0)191.4 (107.5, 309.5).5613 Prone positioning while awake, nonintubated, n (%)4 (5.7)3 (6.1)1 (4.8)1.0000 Prone positioning while intubated, n (%)3 (15.0)0 (0.0)3 (16.7)1.0000 Neuromuscular blockade, n (%)15 (75.0)0 (0.0)15 (83.3).0526Mechanical support ECMO, n (%)1 (1.4)1 (2)0 (0.0).1053 RRT, n (%)1 (1.4)0 (0.0)1 (4.8).3000Outcomes Sepsis syndrome, n (%)57 (81.4)38 (77.6)19 (90.5).3173 Severe sepsis syndrome, n (%) \[n = 12\]12 (21.1)2 (5.3)10 (52.6)\<.0001 AKI, n (%)9 (12.9)5 (10.2)4 (19.0).4366 Cardiac arrest, n (%)2 (2.9)0 (0)2 (2.9)Status on hospital day 14, n (%)\<.0001 Discharged47 (69.1)42 (89.4)5 (23.8) Hospitalized (floor)5 (7.4)4 (8.5)1 (4.8) Hospitalized (PICU)14 (20.6)1 (2.1)13 (61.9) Mortality2 (2.9)0 (0.0)2 (9.5)Status on hospital day 28, n (%)[†](#tbl3fndagger){ref-type="table-fn"} \[n = 70\] Discharged55 (78.5)46 (93.8)9 (42.9) Hospitalized (floor)4 (5.7)2 (4.1)2 (9.5) Hospitalized (PICU)9 (12.8)1 (2)8 (38.1) Mortality2 (2.8)02 (9.5)[^6][^7][^8]

Hydroxychloroquine, remdesivir, and antibiotics \>48 hours were used more often in the ARDS group (*P* \< .05 for all). Corticosteroids were used in 23 patients and 4 patients were treated with immunomodulatory therapies (3 with tocilizumab and 1 with anakinra); none received intravenous immunoglobulin or convalescent plasma.

Prone positioning was used in 7 (10%) of patients, of whom 4 had ARDS. A greater proportion of patients with ARDS received noninvasive mechanical ventilation than patients without ARDS (47.6% vs 8.2%, *P* = .0004). Twenty patients (28.6%) required invasive mechanical ventilation (IMV; 85.6% in the ARDS group vs 4.1% in non-ARDS group, *P* \< .0001), 4 of whom were intubated before PICU admission. Of the 16 who required IMV in a PICU, respiratory support before intubation included oxygen by nasal cannula in 4, high-flow nasal cannula oxygen in 4, and bi-level positive airway pressure in 7 patients.

Of the 21 patients with ARDS, 4 had mild, 12 had moderate, and 5 had severe ARDS. Of these, 18 required IMV: 3 with mild ARDS, 10 with moderate ARDS, and 5 with severe ARDS ([Figure 2](#fig2){ref-type="fig"} ). The 3 patients with mild ARDS who required IMV had significant comorbidities, which included malignancy in 2 patients and severe obesity (BMI 51 kg/m^2^) in 1 patient. The median duration of mechanical ventilation in the ARDS group was 218.9 (139.8, 310.4) hours with 9 (50%) of these 18 patients still hospitalized and requiring invasive mechanical ventilation on day 14, and 7 (38.9%) on day 28 of hospitalization ([Table III](#tbl3){ref-type="table"}). Inhaled nitric oxide was used in 2 patients (2.8%).Figure 2Oxygenation and ventilatory characteristics of intubated patients with COVID-19. *FiO*~*2*~, fraction of inspired oxygen; *MAP*, mean arterial pressure; *PEEP*, positive end-expiratory pressure; *P/F*, arterial pO~2~ divided by the FIO~2~; *pO*~*2*~, partial pressure of oxygen.

One patient (1.4%) was cannulated to venoarterial extracorporeal membrane oxygenation support for acute decompensated heart failure in the setting of the previously diagnosed condition of dilated cardiomyopathy. Two patients (2.9%) required cardiopulmonary resuscitation, 1 of whom survived. Extracorporeal cardiopulmonary resuscitation was not used in any center for this cohort of patients.

By hospital day 14, 49 patients (70%) were discharged home; 14 (20%) remain hospitalized in PICU, and 5 (7.1%) remain hospitalized out of the PICU. Two patients (2.9%) died, one after withdrawal of life-sustaining therapies associated with end-stage osteosarcoma with extensive pulmonary metastases. The second death occurred in a patient with hemoglobinopathy who suffered from a hypoxic bradycardic arrest without return of spontaneous circulation after cardiopulmonary resuscitation.

By hospital day 28, 55 patients (78.6%) were discharged home; 9 (12.9%) remained hospitalized in PICU, and 4 (5.7%) remained hospitalized out of the PICU. Mortality remained at 2 deaths (2.9%) on hospital day 28. The patient on extracorporeal membrane oxygenation remained cannulated on day 28 awaiting cardiac transplant/ventricular assist device placement. The standardized mortality rate at hospital day 14 and 28 day for our cohort is 3.4, which represents 3.4 times excess mortality than that predicted by the PIM-2 score.

The presence of ARDS was associated with significantly longer PICU and hospital duration of stay (both *P* \< .0001, [Figure 3](#figE3){ref-type="fig"}, A and B \[available at [www.jpeds.com](http://www.jpeds.com){#intref0015}\]). In a multivariable analysis of time to discharge, ARDS (but not race or comorbidity) was independently associated with lower probability of PICU and hospital discharge (*P* = .001 for both) and black/Latino race was associated with greater probability of hospital discharge by day 28 (*P* = .04) ([Tables IV](#tbl4){ref-type="table"} and [V](#tbl5){ref-type="table"} ).Table IVMultivariable Cox proportional hazards model of outcome: time to PICU discharge (N = 70)VariablesAHR (95% CI)*P* valueARDS (reference = no)0.08 (0.03-0.21)\<.0001Black/Latino (reference = white)1.78 (0.71-4.48).2210Other race (reference = white)0.91 (0.33-2.51).8539Any comorbidity (reference = no)1.29 (0.68-2.45).4377[^9]Table VMultivariable Cox proportional hazards model of outcome: time to hospital discharge (N = 70)VariablesAHR (95% CI)*P* valueARDS (reference = no)0.10 (0.04-0.27)\<.0001Black/Latino (reference = white)2.76 (0.93-8.24).0685Other race (reference = white)1.00 (0.29-3.42).9951Any comorbidity (reference = no)0.98 (0.51-1.91).9620

Discussion {#sec3}
==========

In this study, we describe clinical manifestations of critically ill children with COVID-19 disease admitted to PICUs in New York City, the epicenter of the COVID-19 pandemic in the US. This study adds to the growing literature on critical illness and outcomes in children with COVID-19, especially that associated with ARDS.

The exact PICU admission rate in children with COVID-19 remains unknown, with previous reports ranging from 1.3% to 28.2%.[@bib1] ^,^ [@bib5] ^,^ [@bib7] ^,^ [@bib13] A systematic review of early studies from China and Singapore identified only 1 critically ill child among 1065 children (0.1%) with confirmed COVID-19.[@bib3] In Spain, only 4 of 41 (16%) confirmed cases were admitted to PICU.[@bib4] In a single-center cohort of 46 hospitalized children positive for SARS-CoV-2 in New York City, 13 (28%) were critically ill, requiring admission to the PICU; 77% of PICU patients developed ARDS; and 61.5% were discharged home.[@bib5] Another study reported with less detail than our study the early experience of critically ill children in a 2-week cross-sectional study of children with COVID-19 admitted to 46 North American PICUs between March 14 and April 3, 2020.[@bib6] Götzinger et al[@bib7] reported an 8% PICU admission rate in their multinational study from Europe. Although some of these studies show a greater rate of critical illness than previously reported, detailed clinical characteristics and multicenter longitudinal outcomes were not reported.

Our study focused on multiple PICUs in the catchment area that includes all of New York City, the epicenter of the COVID-19 pandemic in the US. A previous report was only from 1 of 25 PICUs in New York City.[@bib6] Although our cohort represents approximately 46% of PICU beds, the proportion of critically ill children represented by our cohort is substantially greater because multiple hospitals\' PICU beds were repurposed to accommodate critically ill adults during the pandemic surge. Similarly, a report from China that did not include the epicenter of Wuhan[@bib2] underestimated the presence of critical illness in children compared with studies from Wuhan, the Chinese epicenter.[@bib1] Studies that do not emanate from an epicenter may not represent the experience of a city consumed by pandemic infection. In addition, we report comprehensive details of ventilatory support and oxygenation markers, with concurrent standard scoring of patient criteria for severe sepsis,[@bib14] ARDS,[@bib11] ^,^ [@bib12] and AKI.[@bib13] Compared with previous reports, we provide comprehensive details of patients\' multiorgan involvement, longer enrollment duration (7 weeks vs 2 weeks), and longer outcome follow-up (14 and 28 days vs 8 days).

The median age in our cohort was 15 years, different from early reports that suggested infants and preschool-aged children may be at greater risk of critical illness with COVID-19 infection,[@bib1] but similar to a more recent cross-sectional point-prevalence report from North America.[@bib6] Similar to previous findings,[@bib5] approximately 50% of our critically ill patients reported no known sick contact, indicating a high rate of community spread, which may be explained partially by the high population density of New York City.[@bib16]

There was no difference in the median PIM-2 scores in patients with and without ARDS with a median risk of expected mortality of 0.8%. The overall cohort mortality of 2.8% (all in patients with ARDS) is greater than that expected by the PIM-2 scores. In addition, patients with ARDS had significantly greater prevalence of severe sepsis and required greater levels of respiratory and hemodynamic support.

One of the known risk factors for the development of critical illness in adults is the presence of comorbidities.[@bib17], [@bib18], [@bib19], [@bib20] A high percentage (74%) of our cohort of critically ill children had at least 1 comorbidity, consistent with data from both pediatric and adult studies.[@bib5] ^,^ [@bib6] ^,^ [@bib16], [@bib17], [@bib18], [@bib19] Despite the presence of significant comorbidities, however, these comorbidities were not associated with ARDS in our cohort.

ARDS is reported to occur in 2%-3% of critically ill children[@bib21] and in 17% of critically ill children with viral infections.[@bib22] We found a 30% ARDS prevalence in our COVID-19 cohort, which is substantially greater. When patients with COVID-19 develop ARDS, their intubation rates (86% in our study) are greater than that for other viral infection. One possible reason for a greater intubation rate is the early recommendation to limit use of noninvasive ventilation and to consider early intubation of patients with COVID-19 in an attempt to limit aerosolization of the virus.[@bib23] ^,^ [@bib24]

In patients who required mechanical ventilation, a lung-protective strategy of using a low tidal volume and limiting the plateau pressure as recommended by Pediatric Acute Lung Injury Consensus Conference (PALICC)[@bib11] seem to be effective in COVID-19 ARDS. The moderate median positive end-expiratory pressure of 9.5 cm of water in our cohort is similar to that reported by Grasselli et al[@bib17] in their subcohort of patients \<20 years of age and is not unusual in critically ill children.[@bib25] This is in comparison with the median positive end-expiratory pressure of 14 cm water in adults aged 20-80 years with COVID-19 in the same study,[@bib17] which may reflect relatively preserved compliance of pediatric lungs in the early phase of COVID-19--associated ARDS. Preserved compliance is probably also reflected in the low rate of prone positioning used in our study (only 16.7% for intubated patients with ARDS), again similar to Grasselli et al, who reported a 27% use of prone positioning, with no use in patients younger than 20 years of age.[@bib17] This also may reflect a greater adherence to the PROSEVA study[@bib26] recommendations of prone positioning as well as an absence of conclusive data supporting prone positioning in pediatric patients with ARDS.

More than 30% of the patients in our cohort were from a single borough of New York City, the Bronx. This patient distribution is consistent with a report showing a disproportionate involvement of Bronx County in New York City COVID-19 hospitalizations and deaths, despite the Bronx having the greatest number of hospital beds per 100 000 population and the greatest number of tests performed per 100 000 population of all 5 boroughs of New York City.[@bib27] This may reflect the unique sociodemographic factors of Bronx County,[@bib16] particularly the high density of population/transmission and high rate of poverty, which has been associated with prolonged hospital stay and PICU admission.[@bib28]

Reassuringly, our observed discharge rate (70% by 14 days and 78.6% by 28 days) is greater than that reported in adults.[@bib17], [@bib18], [@bib19], [@bib20] Those with ARDS, however, had longer PICU and hospital LOS compared with those without ARDS.

Our cohort had mortality rates similar to other pediatric studies[@bib5] ^,^ [@bib6] but lower than that reported in adults.[@bib17], [@bib18], [@bib19], [@bib20] However, our 3.5-fold excess standardized mortality of COVID-19 patients is noteworthy. Whether excess mortality ratio is truly related to COVID-19 or is rather an artifact due to low patient numbers or a reflection of sociodemographic factors of New York City is not clear and may be clarified by future large multicenter studies. This early mortality rate of 2.9% in our cohort, however, must be considered in the context of 18.6% of our patients still remaining hospitalized at day 28 and 38.9% of children with ARDS still receiving invasive ventilatory support at day 28.

This study has the limitations of being a retrospective study of a relatively small sample size. Our results may not be applicable to other parts of the country and world, considering the unique demographics of New York City. In addition, this study had not been designed to identify patients with MIS-C, as the first reports to the New York State Department of Health were outside the time frame of our study period.[@bib8] Applying the case definition retroactively following data collection identified some patients who met inflammatory criteria for MIS-C, likely reflecting an overlap in pathophysiology of COVID-19 lung disease, MIS-C, and sepsis. Our cohort primarily represents COVID-19 lower respiratory tract disease, an uncommon feature of MIS-C. Further studies are needed to better understand underlying pathophysiologies and potential spectrum vs distinctive clinical conditions. Further, larger national and international studies are necessary to determine the true incidence and risk factors for critical illness from SARS-CoV-2 infection and the development of ARDS in the pediatric population.

Appendix {#appsec1}
========

Figure 1New York City--wide COVID-19 case distribution.Figure 3**A,** Kaplan--Meier plot: time to PICU discharge for patients with and without ARDS (N = 70, Log-rank test *P* \< .0001). Censored for mortality. Patients still in PICU at study end are censored at last day of follow-up (up to hospital day 28). **B,** Kaplan--Meier plot: time to hospital discharge for patients with and without ARDS (N = 70, log-rank test *P* \< .0001). Censored for mortality. Patients still in hospital at study end are censored at last day of follow-up (up to hospital day 28).
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[^1]: Contributed equally.

[^2]: *bpm*, breaths per minute; *DBP*, diastolic blood pressure; *DKA*, diabetic ketoacidosis; *RR*, respiratory rate; *SBP*, systolic blood pressure; *SpO*~*2*~, arterial oxygen saturation.

[^3]: χ^2^ test, Fisher exact test, or Wilcoxon rank-sum test.

[^4]: *ALT*, alanine aminotransferase; *AST*, aspartate aminotransferase; *B/L*, Bilatera; *BUN*, blood urea nitrogen; *CPK*, creatine phosphokinase; *EF*, ejection fraction; *FEU*, Fibrinogen equivalent unit; *IL*, interleukin; *LV*, left ventricular; *pro-BNP*, pro-B type natriuretic peptide; *LDH*, lactate dehydrogenase; *RV*, right ventricular; *WBC*, white blood cell count.

[^5]: χ^2^ test, Fisher exact test, or Wilcoxon rank-sum test.

[^6]: *BiPAP*, bi-level positive airway pressure; *CPAP*, continuous positive airway pressure; *ECMO*, extracorporeal membrane oxygenation; *HFNC*, high-flow nasal cannula; *IMV*, invasive mechanical ventilation; *NC*, nasal cannula; *RRT*, renal-replacement therapy.

[^7]: χ^2^ test, Fisher exact test, or Wilcoxon rank-sum test.

[^8]: Seven patients did not reach 28 days from PICU admission as they were discharged before this benchmark.

[^9]: *AHR*, adjusted hazard ratio.
